Novavax Inc. NVAX, -2.07% released more extensive data on its Phase 1 trial of a vaccine for COVID-19 Wednesday, and shares rose about 4% in after-hours trading. Novavax previously released findings from the study that said the vaccine candidate induced immune responses and was well-tolerated, but more more data from the study was published Wednesday in The New England Journal of Medicine. "The rapid publication of Phase 1 results from our trial in a prestigious peer-reviewed journal reflects both the importance of the data and the urgent need for an effective vaccine to slow the COVID-19 pandemic," Novavax's president of research and development, Gregory Glenn, said in a news release. After closing with a 2.1% decline at $102.90 in Wednesday's regular session, shares topped $107 in after-hours trading following release of the information. Novavax is one of at least 23 companies working on solutions to COVID-19 amid a global pandemic. Novavax shares have gained nearly 2,500% so far this year.
Reprinted from yahoofinance, the copyrights all reserved by the original author.
면책 조항: 본 게시글에 표현된 견해는 전적으로 작성자의 견해이며 Followme의 공식 입장을 대변하지 않습니다. Followme는 제공된 정보의 정확성, 완전성 또는 신뢰성에 대해 책임을 지지 않으며, 서면으로 명시적으로 언급되지 않는 한 해당 내용을 기반으로 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다.
더 오래된 의견은 없습니다. 소파를 가장 먼저 잡으십시오.